May. 7 at 5:58 PM
🚨
$GCTK JUST TOOK A MAJOR STEP TOWARD DISRUPTING DIABETES TECH
Glucotrack submitted its IDE application to the FDA for a U.S. clinical study of its fully implantable Continuous Blood Glucose Monitoring system.
This isn’t just another wearable CGM. We’re talking:
✅ Implantable blood-based glucose monitoring
✅ No visible on-body sensor
✅ Designed for long-term use
✅ Potential 3-year sensor life
✅ Massive diabetes monitoring market opportunity
If the FDA clears the IDE, GCTK can move into U.S. clinical study mode which is a critical step toward regulatory approval and commercialization.
The diabetes tech space is huge. The CGM market is already proven. But a discreet, long-term implantable solution could be a whole different level.
👀 Watch this one closely. FDA clearance could be the spark that puts GCTK on a lot more radars.
Communicated - Disclaimer:
https://fh.bio/jcoop
Sector Peers:
$DXCM $ABT $PODD $TNDM